MétaCan
Menu
Back to cohort
Record W4385384941 · doi:10.1177/26330040231188979

The IRDiRC Chrysalis Task Force: making rare disease research attractive to companies

2023· article· en· W4385384941 on OpenAlexaff
Katherine Beaverson, Daria Julkowska, Mary Catherine V. Letinturier, Annemieke Aartsma‐Rus, Jennifer Austin, Juan A. Bueren, Simon Frost, Misako Hamamura, Jane Larkindale, Greg LaRosa, Rita Mágenheim, Annamaria Merico, Anna M.G. Pasmooij, Vinciane Pirard, Nicholas Ekow Thomford, Michihiko Wada, Durhane Wong‐Rieger, Adam L. Hartman

Bibliographic record

VenueTherapeutic Advances in Rare Disease · 2023
Typearticle
Languageen
FieldBiochemistry, Genetics and Molecular Biology
TopicCRISPR and Genetic Engineering
Canadian institutionsnot available
FundersNational Institutes of HealthNational Institute of Neurological Disorders and StrokeInstitut National de la Santé et de la Recherche MédicaleEuropean CommissionAustralian Government
KeywordsTask forceTask (project management)Investment (military)DiseasePublic relationsGrant fundingBusinessPsychologyMedicinePolitical scienceMarketingManagementEconomicsPathologyPublic administration

Abstract

fetched live from OpenAlex

Background: The International Rare Diseases Research Consortium (IRDiRC) is an international initiative that aims to use research to facilitate rapid diagnosis and treatment of rare diseases. Objective: IRDiRC launched the Chrysalis Task Force to identify key financial and nonfinancial factors that make rare disease research and development attractive to companies. Methods: The Chrysalis Task Force was comprised of thought leaders from companies, patient advocacy groups, regulatory agencies, and research funders. The Task Force created a survey that was distributed to companies of different sizes with varied investment portfolios and interests in rare disease research. Based on the survey results, the Task Force then conducted targeted interviews. Results: The survey and interview respondents identified several factors that make rare disease research and development attractive (e.g. a good understanding of the underlying biology) as well as barriers (e.g. absence of an advocacy organization representing the affected community's needs). The concept of Return On Investment allowed the exploration of factors that were weighed differently by survey and interview respondents, depending on a number of intrinsic and extrinsic issues. Conclusions: The Chrysalis Task Force identified factors attributable to rare disease research and development that may be of interest to and actionable by funders, academic researchers, patients and their families, companies, regulators, and payers in the medium term to short term. By addressing the identified challenges, involved parties may seek solutions to significantly advance the research and development of treatments for rare diseases.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.184
metaresearch head score (Gemma)0.190
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesMetaresearch
Consensus categoriesnone
DomainCandidate signal: Incentives · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: Not applicable
GenreCandidate signal: Commentary · Consensus signal: Commentary
Teacher disagreement score0.816
Threshold uncertainty score0.973

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.1840.190
Meta-epidemiology (narrow)0.0020.001
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0040.002
Science and technology studies0.0120.005
Scholarly communication0.0110.005
Open science0.0050.018
Research integrity0.0150.010
Insufficient payload (model declined to judge)0.0120.007

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.032
GPT teacher head0.420
Teacher spread0.388 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

Study designNot applicable
DomainIncentives
GenreCommentary

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations7
Published2023
Admission routes1
Has abstractyes

Explore more

Same venueTherapeutic Advances in Rare DiseaseSame topicCRISPR and Genetic EngineeringFrench-language works237,207